Marc Grasso
Known title: Chief Financial OfficerCIK: 0001748894
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Alector (ALEC) sees purchases by NVIDIA and Merck. Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.
Transaction History
| KYTX | ▲ Buy | Grant | 10,000 | $0 | 3/13/2026 | View on chart |
| ALEC | ▼ Sell | Open Market | 16,488 | $22K | 6/2/2025 | View on chart |
| ALEC | ▼ Sell | Open Market | 18,091 | $27K | 3/3/2025 | View on chart |
| ALEC | ▼ Sell | Open Market | 16,489 | $42K | 12/2/2024 | View on chart |
| ALEC | ▲ Buy | Grant | 216,400 | $0 | 10/1/2024 | View on chart |
| ALEC | ▼ Sell | Open Market | 7,297 | $36K | 9/3/2024 | View on chart |
| ALEC | ▼ Sell | Open Market | 6,920 | $33K | 6/3/2024 | View on chart |
| ALEC | ▼ Sell | Open Market | 5,716 | $40K | 3/4/2024 | View on chart |
| ALEC | ▼ Sell | Open Market | 4,574 | $25K | 12/4/2023 | View on chart |
| ALEC | ▲ Buy | Grant | 123,000 | $0 | 10/1/2023 | View on chart |
| ALEC | ▼ Sell | Open Market | 1,114 | $6K | 9/5/2023 | View on chart |
| ALEC | ▼ Sell | Open Market | 1,050 | $7K | 6/2/2023 | View on chart |
| ALEC | ▼ Sell | Open Market | 1,291 | $11K | 3/2/2023 | View on chart |
| ALEC | ▲ Buy | Grant | 35,702 | $0 | 10/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials
Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.